[{"id":"1c2892ea-1261-4dae-afe1-c46131b3f056","acronym":"","url":"https://clinicaltrials.gov/study/NCT07039760","created_at":"2025-06-28T13:40:51.525Z","updated_at":"2025-06-28T13:40:51.525Z","phase":"Phase 1","brief_title":"Asciminib With or Without Sildenafil for Brain Tumors","source_id_and_acronym":"NCT07039760","lead_sponsor":"Washington University School of Medicine","biomarkers":" CRKL • ABL2","pipe":"","alterations":" ","tags":["CRKL • ABL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib) • sildenafil"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-06-26"},{"id":"9ae7ce18-a20f-474a-a6f4-17a8162e7b3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01817751","created_at":"2021-03-25T16:50:49.924Z","updated_at":"2024-07-02T16:35:51.245Z","phase":"Phase 2","brief_title":"Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT01817751","lead_sponsor":"Virginia Commonwealth University","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA expression","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • sildenafil"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 04/11/2013","start_date":" 04/11/2013","primary_txt":" Primary completion: 08/27/2020","primary_completion_date":" 08/27/2020","study_txt":" Completion: 10/30/2027","study_completion_date":" 10/30/2027","last_update_posted":"2023-04-06"}]